Moderna’s UK Expansion Fails to Impress as Shares Decline

Moderna shares experienced a notable downturn this week, declining nearly 5% on Thursday to close at approximately €21. This sell-off occurred despite the company’s official unveiling of a major new research and manufacturing facility in Oxfordshire, UK. The market’s reaction highlights investor concerns that overshadow the positive announcement of a significant long-term investment.

The newly inaugurated Moderna Innovation and Technology Centre (MITC) represents a cornerstone of the company’s ten-year partnership with the British government. Moderna has committed over £1 billion to this venture, which will focus on research and development. The state-of-the-art facility boasts an annual production capacity of up to 100 million mRNA vaccine doses, a figure that can be scaled to 250 million during a pandemic. The project is expected to... Read more...